Arcus Capital Partners LLC continued to hold its stake in Opko Health, Inc. (NASDAQ:OPK) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the biotechnology company’s stock at the end of the second quarter. Arcus Capital Partners LLC’s holdings in Opko Health were worth $132,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in OPK. Credit Suisse AG raised its holdings in shares of Opko Health by 122.0% during the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock worth $5,976,000 after acquiring an additional 410,445 shares during the period. State Street Corp raised its holdings in shares of Opko Health by 40.3% during the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after acquiring an additional 3,138,685 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its holdings in shares of Opko Health by 14.8% during the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after acquiring an additional 17,458 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Opko Health during the first quarter worth $4,450,000. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Opko Health by 7.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after acquiring an additional 27,940 shares during the period. 22.46% of the stock is currently owned by institutional investors.
In other news, CEO Phillip Md Et Al Frost bought 5,400 shares of the stock in a transaction dated Thursday, July 20th. The stock was bought at an average price of $6.46 per share, for a total transaction of $34,884.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $19,825,423.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders bought 925,800 shares of company stock valued at $5,667,905. 40.19% of the stock is currently owned by corporate insiders.
A number of equities research analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Opko Health in a report on Thursday, August 17th. They set an “overweight” rating and a $20.00 price objective on the stock. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a report on Friday, July 21st. Barrington Research raised their price objective on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, July 18th. BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Jefferies Group LLC restated a “hold” rating and set a $8.00 price objective on shares of Opko Health in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Opko Health has an average rating of “Buy” and a consensus target price of $13.97.
Shares of Opko Health, Inc. (NASDAQ:OPK) traded up 1.02% during midday trading on Friday, reaching $6.95. 1,183,151 shares of the company’s stock traded hands. The company has a 50 day moving average of $6.53 and a 200 day moving average of $6.73. Opko Health, Inc. has a 52-week low of $5.85 and a 52-week high of $12.15. The firm’s market cap is $3.89 billion.
Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $314.20 million during the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 earnings per share. On average, equities analysts predict that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.